title: [Intraocular cytokines imbalance in retinal vein occlusion and its impact on the efficacy of anti-angiogenic therapy].
abstract: OBJECTIVE
  To study the concentrations of intraocular cytokines in patients with retinal vein occlusion (RVO) before and after intravitreal ranibizumab injection and to compare the results with clinical activity of the disease and treatment efficacy.
  
  
  METHODS
  A comprehensive ophthalmological examination of 44 patients with RVO and macular edema was performed. Intraocular fluid was first collected before the intravitreal injection. Cytokines concentrations were measured using Bio-Plex Pro Human Cytokine 27-plex Panel (Bio-Rad Laboratories, USA) for flow cytometry. The test was repeated 1 month after the injection.
  
  
  RESULTS
  A total of 11 cytokines were reliably detected. After ranibizumab injections certain angiogenic (VEGF) and proinflammatory (IL-6, IL-8, IL-13, IL-15, MCP-1) factors appeared to be significantly suppressed. Clinical efficacy of the therapy correlated with the degree of cytokines suppression, which in turn depended on the severity of ocular involvement at baseline.
  
  
  CONCLUSIONS
  Retinal vein occlusion pathogenesis involves a cascade of immune and inflammatory processes, including activation of not only VEGF but also quite a few inflammatory and chemotactic factors, whose activity depends on the extent of ischemic damage in the retina.
authors.affiliation: Irkutsk branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 337 Lermontova St., Irkutsk, Russian Federation, 664033; Irkutsk State Medical University, 1 Krasnogo vosstaniya St., Irkutsk, Russian Federation, 664003.
authors.forename: A G
authors.initials: AG
authors.lastname: Shchuko
authors.affiliation: Irkutsk branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 337 Lermontova St., Irkutsk, Russian Federation, 664033; Irkutsk State Medical University, 1 Krasnogo vosstaniya St., Irkutsk, Russian Federation, 664003.
authors.forename: I V
authors.initials: IV
authors.lastname: Zlobin
authors.affiliation: Irkutsk branch of the Academician S.N. Fyodorov IRTC 'Eye Microsurgery', 337 Lermontova St., Irkutsk, Russian Federation, 664033; Irkutsk State Medical Academy of Continuing Education, 100 Yubileynyy mikrorayon, Irkutsk, Russian Federation, 664049.
authors.forename: T N
authors.initials: TN
authors.lastname: Yur'eva
authors.affiliation: Research Institute of Fundamental and Clinical Immunology, 14 Yadrintsevskaya St., Novosibirsk, Russian Federation, 630099.
authors.forename: A A
authors.initials: AA
authors.lastname: Ostanin
authors.affiliation: Research Institute of Fundamental and Clinical Immunology, 14 Yadrintsevskaya St., Novosibirsk, Russian Federation, 630099.
authors.forename: E R
authors.initials: ER
authors.lastname: Chernykh
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001082:Aqueous Humor / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D003941:Diagnostic Techniques, Ophthalmological; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D000069579:Ranibizumab